Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: A multicentre phase II study

British Journal of Haematology

Volumn 166, Issue 4, 2014, Pages 514-520

  Evens, Andrew M ^a   Smith, Mitchell R ^b   Lossos, Izidore S ^c   Helenowski, Irene ^d   Millenson, Michael ^e   Winter, Jane N ^d   Rosen, Steve T ^d   Gordon, Leo I ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Bortezomib; Cancer; Follicular lymphoma; Prognosis; Treatment

Indexed keywords

BORTEZOMIB; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG TOLERANCE; EFFUSION; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; INFECTION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; INTESTINE OBSTRUCTION; LOSS OF APPETITE; MALE; MALIGNANT EFFUSION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

BORTEZOMIB; CANCER; FOLLICULAR LYMPHOMA; PROGNOSIS; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904986323     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12915     Document Type: Article

References (29)

1. Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Vaughan, G., Hudson, G.V. & Linch, D.C. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet, 362, 516-522.
2. Bachy, E., Houot, R., Morschhauser, F., Sonet, A., Brice, P., Belhadj, K., Cartron, G., Audhuy, B., Ferme, C., Feugier, P., Sebban, C., Delwail, V., Maisonneuve, H., Le Gouill, S., Lefort, S., Brousse, N., Foussard, C., Salles, G. & Groupe d'Etude des Lymphomes de, l.A. (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica, 98, 1107-1114.
3. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Celigny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 1110-1117.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
5. Coiffier, B., Osmanov, E.A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., Teixeira, A., Walewski, J., de Vos, S., Crump, M., Shpilberg, O., Esseltine, D.L., Zhu, E., Enny, C., Theocharous, P., van de Velde, H., Elsayed, Y.A., Zinzani, P.L. & Investigators, L.Y.M.s. (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12, 773-784.
6. Coiffier, B., Li, W., Henitz, E.D., Karkera, J.D., Favis, R., Gaffney, D., Shapiro, A., Theocharous, P., Elsayed, Y.A., van de Velde, H., Schaffer, M.E., Osmanov, E.A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., Teixeira, A., Romejko-Jarosinska, J., de Vos, S., Crump, M., Shpilberg, O., Zinzani, P.L., Cakana, A., Esseltine, D.L., Mulligan, G. & Ricci, D. (2013) Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clinical Cancer Research, 19, 2551-2561.
7. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. & Solal-Celigny, P. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 97, 101-106.
8. Di Bella, N., Taetle, R., Kolibaba, K., Boyd, T., Raju, R., Barrera, D., Cochran E.W. Jr, Dien, P.Y., Lyons, R., Schlegel, P.J., Vukelja, S.J., Boston, J., Boehm, K.A., Wang, Y. & Asmar, L. (2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 115, 475-480.
9. Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A.M., Pulsoni, A., Merli, F., Arcaini, L., Angrilli, F., Stelitano, C., Gaidano, G., Dell'olio, M., Marcheselli, L., Franco, V., Galimberti, S., Sacchi, S. & Brugiatelli, M. (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 31, 1506-1513.
10. Fowler, N., Kahl, B.S., Lee, P., Matous, J.V., Cashen, A.F., Jacobs, S.A., Letzer, J., Amin, B., Williams, M.E., Smith, S., Saleh, A., Rosen, P., Shi, H., Parasuraman, S. & Cheson, B.D. (2011) Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. Journal of Clinical Oncology, 29, 3389-3395.
11. Friedberg, J.W., Vose, J.M., Kelly, J.L., Young, F., Bernstein, S.H., Peterson, D., Rich, L., Blumel, S., Proia, N.K., Liesveld, J., Fisher, R.I., Armitage, J.O., Grant, S. & Leonard, J.P. (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, 117, 2807-2812.
12. Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 4416-4423.
13. Hainsworth, J.D., Litchy, S., Burris, H.A. 3rd, Scullin, D.C. Jr, Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. Journal of Clinical Oncology, 20, 4261-4267.
14. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dolken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Hoffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M. & von Grunhagen, U. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 1986-1992.
15. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
16. Kahl, B.S., Williams, M.E., Hong, F., Gascoyne, R. & Horning, S.J. (2007) Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood, 110, 3420a.
17. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 1417-1423.
18. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 4579-4586.
19. Martinelli, G., Schmitz, S.F., Utiger, U., Cerny, T., Hess, U., Bassi, S., Okkinga, E., Stupp, R., Stahel, R., Heizmann, M., Vorobiof, D., Lohri, A., Dietrich, P.Y., Zucca, E. & Ghielmini, M. (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28, 4480-4484.
20. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
21. O'Connor, O.A., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Gerecitano, J., Gonen, M., Dumitrescu, O., Sarasohn, D., Butos, J., Neylon, E., Mac-Gregor Cortelli, B., Blumel, S., Evens, A.M., Zelenetz, A.D., Wright, J., Cooper, B., Winter, J. & Vose, J. (2010) Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical Cancer Research, 16, 719-726.
22. Petrucci, M.T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M.A., Blau, I.W., Drach, J., Angermund, R., Allietta, N., Broer, E., Mitchell, V. & Bladé, J. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 160, 649-659.
23. Ribrag, V., Tilly, H., Casasnovas, O., Bosly, A., Bouabdallah, R., Delarue, R., Boue, F., Bron, D., Feugier, P., Haioun, C., Offner, F. & Coiffier, B. (2013) Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). European Journal of Cancer, 49, 904-910.
24. Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grunhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Durk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W. & Study group indolent, L. (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381, 1203-1210.
25. Salles, G., Mounier, N., de Guibert, S., Morschhauser, F., Doyen, C., Rossi, J.F., Haioun, C., Brice, P., Mahe, B., Bouabdallah, R., Audhuy, B., Ferme, C., Dartigeas, C., Feugier, P., Sebban, C., Xerri, L. & Foussard, C. (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood, 112, 4824-4831.
26. Salles, G., Seymour, J.F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 42-51.
27. Sehn, L.H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R.D., Sussman, J., Chen, B.E., Djurfeldt, M., Shepherd, L., Couban, S. & Crump, M. (2011) Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 29, 3396-3401.
28. Solal-Celigny, P., Lepage, E., Brousse, N., Tendler, C.L., Brice, P., Haioun, C., Gabarre, J., Pignon, B., Tertian, G., Bouabdallah, R., Rossi, J.F., Doyen, C. & Coiffier, B. (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Journal of Clinical Oncology, 16, 2332-2338.
29. de Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T. & Boral, A.L. (2009) Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. Journal of Clinical Oncology, 27, 5023-5030.